Onco360 Chosen as Pharmacy Provider for Rezurock
The FDA had approved Kadmon's therapy for graft-versus-host disease July 16.
Kadmon Pharmaceuticals has selected Onco360 as the pharmacy provider for Rezurock (belumosudil). Onco360 in Louisville, K.Y., is a provider of oncology pharmacy services and dispenses nationally through its network of URAC-, ACHC-, and NABP digital-accredited pharmacies. It is a specialty pharmacy brand of PharMerica Corporation.
The FDA approved Rezurock on July 16 for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.
Rezurock is expected to be available by late August 2021
“As a provider of this key treatment, Onco360 is committed to supporting the highly specialized needs of chronic GVHD patients,” Benito Fernandez, chief commercial officer, Onco360, said in a statement.
Rezurock is the first FDA-approved small molecule inhibitor of ROCK2, a signaling pathway that modulates inflammatory responses and fibrotic processes. The approval is based on safety and efficacy results from ROCKstar (KD025-213), a randomized, open-label, multicenter pivotal trial of Rezurock in 65 patients with cGVHD who had received two to five prior lines of systemic therapy.
The therapy achieved an overall response rate of 75% through cycle 7 day 1 of treatment with 6% of patients achieving a complete response and 69% achieving a partial response. Sixty-two percent (62%) of responders did not require new systemic therapy for at least 12 months following response.
Private Equity in Healthcare: Colonoscopy Prices Soar While Care Remains the Same
July 11th 2025Private equity acquisitions have increased rapidly across all aspects of healthcare, with gastroenterology practices experiencing the highest share. In the U.S., approximately 13% of gastroenterologists work in practices owned by private equity groups.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
